Emalex raised $250M for a Phase 3 Tourette drug trial as late-stage funding dried up

Emalex Biosciences develops central nervous system drug treatments, with its lead program targeting Tourette syndrome and a second targeting Willis-Ekbom disease (restless leg syndrome).

That positive Phase 2 data for its Tourette drug would let Emalex raise late-stage capital even as investors pulled back from late-stage biotech.

Raised $35M in Series C funding the prior year, per Crunchbase data, before this $250M Series D.

Started in 2018 by life-science incubator Paragon Biosciences to develop central nervous system treatments, Emalex zeroed in on Tourette syndrome, a disorder causing repetitive muscle movements and sounds, and Willis-Ekbom disease.

After publishing Phase 2 results showing its drug candidate reduced motor and audible tics better than placebo, Emalex closed a $250M Series D led by Bain Capital, with Paragon Biosciences, Valor Equity Partners and Fidelity Management and Research also participating. The funding was earmarked for a Phase 3 trial expected to enroll 220 patients across 90 locations — one of the largest clinical trials in the space and the last stretch before the drug could be commercialized.

Positive Phase 2 data, published before the raise, gave investors concrete clinical evidence rather than a pitch based on market timing.

The late-stage funding gap (80% versus early-stage) made large late-stage rounds rare in 2022, so Bain Capital's lead signaled unusual conviction in Emalex specifically.

The Phase 3 trial's scale — 220 patients across 90 locations — matched the size of the raise to a defined, near-final regulatory milestone rather than open-ended runway.

In a funding drought that hits late-stage companies hardest, clinical proof of concept — not market timing — is what still gets a large round closed.

As of 2022-11-03, Emalex had closed its $250M Series D and was directing the funds toward a Phase 3 clinical trial for its Tourette syndrome drug candidate, expected to enroll 220 patients across 90 locations as the final step before potential commercialization.